Compound k, intestinal metabolite of ginsenoside, attenuates hepatic lipid accumulation via AMPK Activation in human hepatoma cells

Journal of Agricultural and Food Chemistry

Volumn 57, Issue 4, 2009, Pages 1532-1537

  Kim, Do Yeon ^a   Yuan, Hai Dan ^a   Chung, In Kyung ^b   Chung, Sung Hyun ^a  

^a Kyung Hee University   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

Author keywords

ACC; AMPK; Compound K; Diabetes; Hepg2 hepatoma cells; Hyperlipidemia; PPAR R; SREBP1c

Indexed keywords

GINSENOSIDE; GINSENOSIDE M1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ARTICLE; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION; GENETICS; HUMAN; INTESTINE; LIPID METABOLISM; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; ENZYME ACTIVATION; GENE EXPRESSION; GINSENOSIDES; HUMANS; INTESTINES; LIPID METABOLISM; LIVER; LIVER NEOPLASMS;

PANAX GINSENG;

EID: 64549086074     PISSN: 00218561     EISSN: None     Source Type: Journal    
DOI: 10.1021/jf802867b     Document Type: Article

References (20)

1. Marchesini, G.; Brizi, M.; Bianchi, G.; Tomassetti, S.; Buqianesi, E.; Lenzi, M.; McCullough, A.; Natale, S.; Forlani, G.; Mel-chionda, N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50 (8), 1884-1850.
2. Hardie, D. G; Scott, J. W.; Pan, D. A.; Hudson, E. R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 2003, 546, 113-120.
3. Hardie, D. H.; Carling, D. The AMP-activated protein kinase. Fuel gauge of the mammalian cell? Eur. J. Biochem. 1997, 246, 259-273.
4. Viollet, B.; Foretz, M.; Guigas, B.; Horman, S.; Dentin, R.; Bertrand, L.; Hue, L.; Andreelli, F. Activation of AMP-activated protein kinase in the liver:a new strategy for the management of metabolic hepatic disorders. J. Physiol. 2006, 574, 41-53.
5. Brusq, J. M.; Ancellin, N.; Grondin, P.; Guillard, R.; Martin, S.; Saintillan, Y.; Issandou, M. Inhibition of lipid synthesis through activation of AMP kinase; an additional mechanism for the hypolipidemic effects of berberine. J. Lipid. Res. 2006, 47 (6), 1281-1288.
6. Wakabayashi, C.; Murakami, K.; Hasegawa, H; Murata, H. J.; Saiki, I. An intestinal bacterial metabolite of ginseng protopanaxa-diol saponins has the ability to induce apoptosis in tumor cells. Biochem. Biophys. Res. Commun. 1998, 246 (3), 725-730.
7. Lee, S. J.; Ko, W. G.; Km, J. H.; Sung, J. H.; Moon, C. K.; Lee, B. H. Induction of apoptosis by a novel intestinal metabolite of ginseng saponin via cytochrome c-mediated activation of caspase-3 protease. Biochem. Pharmacol. 2000, 60 (5), 677-85.
8. Choi, K.; Kim, M.; Rhy, J.; Choi, C. Ginsenosides compound K and Rh (2) inhibit tumor necrosis factor-alpha-induced activation of the NF-kappaB and JNK pathways in human astroglial cells. Neurosci. Lett. 2007, 421 (1), 37-41.
9. Yoon, S. H.; Han, E. J.; Sung, J. H.; Chung, S. H. Anti-diabetic effects of compound K versus metformin versus compound K-metformin combination therapy in diabetic db/db mice. Biol. Pharm. Bull. 2007, 30 (11), 2196-2200. (
10. 10) Han, G. C.; Ko, S. K; Sung, J. H; Chung, S. H. Compound K enhances insulin secretion with beneficial metabolic effects in db/db mice. J. Agric. Food. Chem. 2007, 55 (26), 10641-10648.
11. Akli, S.; Chelly, J.; Lacorte, J. M.; Poenaru, L.; Kahn, A. Seven novel Tay-Sachs mutations detected by chemical mismatch cleavage of PCR-amplified cDNA fragments. Genomics 1991, 11, 12-134.
12. Viollet, B.; Foretz, M.; Guigas, B.; Horman, S.; Dentin, R.; Bertrand, L.; Hue, L.; Andreelli, F. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J. Physiol. 2006, 574, 41-53.
13. Clark, J.; Diehl, A. Hepatic steatosis and type 2 diabetes mellitus. Curr. Diabetes Rep. 2002, 2, 210-215.
14. Kelley, D. E.; McKolanis, T. M.; Hegazi, R. A.; Kuller, L. H; Kalhan, S. C. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2003, 285, E906-E916.
15. Kim, J. K.; Gavrilova, O.; Chen, Y.; Reitman, M. L.; Shulman, G. I. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J. Biol. Chem. 2002, 275, 8456-8460.
16. Hardie, D. G. The AMP-activated protein kinase pathway-new players upstream and downstream. J. Cell Sci. 2004, 117, 5479-5487.
17. Woods, A.; Johnstone, S. R.; Dickerson, K; Leiper, F. C.; Fryer, L. G.; Neumann, D.; schlattner, U.; Wallimann, T.; Carison, M.; Carling, D. LKB1 is the upstream kinase in the AMP-activated protein kinase in the AMP-activated protein kinase cascade. Curr. Biol. 2003, 13, 2004-2008.
18. Shaw, R. J.; Lamia, K. A.; Vasquez, D.; Koo, S. H; Bardeesy, N.; Depinho, R. A.; Montminy, M.; Cantley, L. C. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310, 1642-1646.
19. Eberle, D.; Heqarty, B.; Bossard, P.; Ferre, P.; Foufelle, F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004, 86, 839-848.
20. Expenshade, P. J.; Hughes, A. L. Regulation of Sterol Synthesis in Eukaryotes. Annu. Rev. Genet. 2007, 41, 401-427.